RxDoctor Payments Data

Margaret Colleran, MD

Internal Medicine · Riverview, FLNPI 1457356677

Payments from drug & device makers

$6,850in general payments, 2019–2025

Across 413 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$649
  • Novo Nordisk$613
  • AbbVie$563
  • Amgen$489
  • AstraZeneca$486
  • Boehringer Ingelheim$362
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$6,836100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,850 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$280,452
Medicare patients
482
Services billed
4,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$100,217
MounjaroTirzepatide32$37,565
OzempicSemaglutide21$32,296
XareltoRivaroxaban23$29,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$27,498
MyrbetriqMirabegron24$25,791
JardianceEmpagliflozin15$22,798
FarxigaDapagliflozin Propanediol26$12,245
TrulicityDulaglutide11$10,962
ArexvyRsvpref3 Antigen/As01e/Pf35$10,931
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$10,336
PremarinEstrogens, Conjugated18$7,780
Atorvastatin Calcium812$7,381
Repatha SureclickEvolocumab12$6,948
LinzessLinaclotide12$6,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$232$107,997131 claims
Lilly USA, LLCMounjaro, Trulicity$649$48,52643 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$96$44,20584 claims
Novo NordiskOzempic$613$32,29621 claims
Johnson & JohnsonXarelto$311$29,73923 claims
Astellas Pharma US IncMyrbetriq$200$25,79124 claims
Boehringer IngelheimJardiance$362$22,79815 claims
AstraZenecaFarxiga$486$12,24526 claims
AbbVieLinzess, Synthroid$563$8,83849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →